Biotechnology Company
Appears in 1 story
Daraxonrasib in Phase 3 trials (RASolute 302 readout expected 2026); acquisition talks with Merck collapsed January 2026
For 40 years, the KRAS gene has been oncology's white whale—present in 90% of pancreatic cancers, yet resistant to every drug thrown at it. Scientists called it 'undruggable.' On January 28, 2026, Spanish researchers published results showing they had achieved what decades of effort could not: complete and lasting tumor elimination in mice using a triple-drug combination that blocks KRAS and two downstream pathways simultaneously.
Updated Jan 30
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
